Open AccessNSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy
Author(s) -
Diego Kauffmann-Guerrero,
Rudolf M. Huber,
Simone Reu,
Amanda Tufman,
Pontus Mertsch,
Zulfiya Syunyaeva,
Andreas Jung,
Kathrin Kahnert
Publication year - 2017
Publication title -
respiration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.264
H-Index - 81
eISSN - 1423-0356
pISSN - 0025-7931
DOI - 10.1159/000484175
Subject(s) - medicine , lung cancer , tyrosine kinase inhibitor , mutation , epidermal growth factor receptor , t790m , oncology , gefitinib , tyrosine kinase , cancer research , cancer , receptor , genetics , biology , gene
Generally, tyrosine kinase inhibitor (TKI) therapy is recommended in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring a classic epidermal growth factor receptor (EGFR) mutation. However, the response of patients with rare or complex EGFR mutations to TKI treatment is not predictable, nor is the prognosis for such patients.